Clinical trial
Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft…
NCT00452361 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00452361 |
|---|---|
| Title | Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient |
| Official title | A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipient |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Sirolimus+MMF or MPS or AZA+Steroid, Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid |
| Enrollment | 31 |
| Start date | Apr 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Mar 27, 2007 |
| Last update posted | Sep 3, 2012 |
| Countries | Taiwan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: